News & Events:BNTX

CNBC JPMorgan Remains Bullish On Alibaba And Other Chinese Stocks - Here's Why More Pain Ahead For Ethereum?

Moderna's COVID-19 Vaccine Shows Safety, Effectiveness For Children Under 17 Years

According to the FDA briefing document, Pfizer Inc  -BioNTech's SE  COVID-19 vaccines were effective and safe for children aged six months to 4 years. The FDA reviewers said that their evaluation did not reveal any new safety concerns related to using the vaccine in young children. The FDA analysis of data from Pfizer's trial was published ahead of a June 14-15 meeting of its outside advisers.

Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern

A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 70% with bearish.

MAINZ, Germany, June 9, 2022 — BioNTech SE (BNTX) will welcome its African partners for the first time on the African continent and provide an update on the joint establishment of mRNA manufacturing facilities and vaccine development plans.

Reuters Blackstone Closes In Crown Bid After Australia Approvals: Reuters United States Helps To Keep Taiwanese Warships In Service State Street Might Tap Credit Suisse As Takeover Interest Wall Street Journal US Schedules Covid-19 Vaccines For Children Below Five Years Bloomberg Here's Why Alibaba Shares Are Trading Lower Premarket After Brief Jump India's Apollo Global, Reliance Make a Bindin...

US Schedules Covid-19 Vaccines For Children Below Five Years

HC Wainwright Says Non-mRNA COVID-19 Option Underappreciated

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax  can now heave a sigh of relief.

COVID-19 Vaccine Patent Waiver Expected Soon, Says WTO Head: Reuters

Pfizer, Inc. is upping its commitment to manufacture its oral COVID-19 pill Paxlovid in the United States. What Happened: Pfizer will invest an incremental $120 million at its Kalamazoo, Michigan facility to augment production of Paxlovid, the pharma giant said in a statement late Monday.

On Friday, shares of BioNTech SE experienced volatile short activity. The overall sentiment for BNTX has been Bearish. The signal from the volatility alert is trending Bullish. Therefore, the recommendation is to Decrease Short Exposure.

Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients

MAINZ, Germany and CHICAGO, June 5, 2022 – BioNTech SE (BNTX) today announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability of the mRNA-based individualized neoantigen specific immunotherapy autogene cevumeran in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancr...

Reuters China Will Lose Ability To Access Amazon's Kindle E-Book Store From 2023 Toshiba Gets Privatization Proposals - Guess How Many Are Interested Delta, United Airlines Positive On Post-Pandemic Spending Biden Visit Might Push For Saudi Arabia And OPEC To Make Up For Russian Oil Loss Wall Street Journal Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five Bloomber...

Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five

MAINZ, GERMANY, June 1, 2022 — At the Annual General Meeting of BioNTech SE (BNTX) held today, June 1, 2022, shareholders voted to reappoint Helmut Jeggle as a member of the Supervisory Board with a majority of 96.44 per cent. In addition, the shareholders passed the proposal of the Management Board and Supervisory Board and resolved to pay a special cash dividend of €2.00 per ordinary share.

On CNBC's "Mad Money Lightning Round," Jim Cramer said he can't recommend Roblox Corp as it is not making money. When asked about Novavax, Inc. , he said, "We have Pfizer Inc. and we have BioNTech SE , and that's what we needed."

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. Among the companies that received the FDA's greenlight were Phathom Pharmaceuticals, Inc. , Bristol-Myers Squibb Company and Novartis AG . On the other hand, Verrica Pharmaceuticals Inc.'s viral skin infection treatment candidate was rejected by the regulator for the third time.